10x Genomics, Inc. (TXG)
After hours:
| Previous close | 22.55 |
| Open | 22.93 |
| Bid | 22.32 x 400 |
| Ask | 22.39 x 400 |
| Day's range | 22.31 - 23.58 |
| 52-week range | 15.28 - 57.90 |
| Volume | |
| Avg. volume | 1,837,195 |
| Market cap | 2.695B |
| Beta (5Y monthly) | 1.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.03 |
| Earnings date | 31 Oct 2024 - 04 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 27.43 |
PR NewswireLausanne Researchers Combine 10x Genomics' Chromium and Xenium for Novel Insights into Resistance and Potential Therapeutics for Brain Cancer
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that its Chromium Single Cell Gene Expression and Xenium In Situ platforms were used in a publication – featured on the cover of Cancer Cell – that sheds light on the role of fibrotic scars in glioblastoma treatment recurrence. The study, led by researchers in the laboratory of Professor Johanna Joyce (University of Lausanne, Switzerland) and the Ludwig Institute for Cancer Research (Lausanne, Switzerl
- PR Newswire
10x Genomics Unveils Chromium Xo: A Low-Cost Instrument to Expand Access to High-Performance Single Cell Research
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of Chromium Xo, a new addition to its fleet of Chromium single cell instruments. Designed to meet the needs of researchers who desire high-quality data on limited budgets, Chromium Xo offers an affordable entry point into routine, high-performance single cell analysis.
- PR Newswire
10x Genomics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, at 10:45 a.m. Eastern Time.
